Digital clinic Embarq Health now features integrated Cirventis virtual health care infrastructure to provide technology-enabled care for its members.
Почему хроническая крапивница возвращается неделями и месяцами, всегда ли виновата аллергия, какие обследования действительно нужны ...
At week 12, both dosing regimens (150mg Q4W and 300mg Q8W) demonstrated statistically significant reductions in weekly urticaria activity score compared with placebo. Topline results were announced ...
Celldex a annoncé des résultats principaux positifs issus des essais de phase 3 EMBARQ-CSU1 et EMBARQ-CSU2 de la société, évaluant deux doses de barzolvolimab chez des patients atteints d’urticaire ...
Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary ...
HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE)-- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company's Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of ...
CHARLESTON, S.C., Sept. 15, 2026 /PRNewswire/ -- Embarq Health has integrated Cirventis' virtual-first healthcare infrastructure to expand access to convenient, technology-enabled care for its members ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results